🇺🇸 Nocardia rubra cell wall skeleton in United States

21 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hypoalbuminaemia — 3 reports (14.29%)
  2. Off Label Use — 3 reports (14.29%)
  3. Blood Glucose Increased — 2 reports (9.52%)
  4. Drug-Induced Liver Injury — 2 reports (9.52%)
  5. Hypocalcaemia — 2 reports (9.52%)
  6. Hypokalaemia — 2 reports (9.52%)
  7. Myelosuppression — 2 reports (9.52%)
  8. Neurotoxicity — 2 reports (9.52%)
  9. Neutrophil Count Decreased — 2 reports (9.52%)
  10. Abdominal Discomfort — 1 report (4.76%)

Source database →

Nocardia rubra cell wall skeleton in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Nocardia rubra cell wall skeleton approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Nocardia rubra cell wall skeleton in United States?

Wan-Guang Zhang is the originator. The local marketing authorisation holder may differ — check the official source linked above.